Hi Mita, I tend to agree with your view and sales projections. The patent expiring in 2017 may have an adverse impact on earnings after this point but will depend on whether the patent can be extended etc. Regarding your other produce opportunity lines - IMO they probably have discounted them as a result of lack of information being released regarding them which could lead to a view of lack of progression. IMO there needs to be more substantial/informative ANN's by the company as IMO recent ANN's are only hammering what has already been said and IMO really a waste of time/money. Market probably sees this as well - so analysts are probably looking at lack of revenue streams, lack of information regarding pipeline projects, probably looking at R&D costs and what, if any, return they may provide but all in all - how can you quantify returns on other "products" if there is no crystal information provided about where they are at?.
ACR Price at posting:
$2.58 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)